BJ-1108, a 6-Amino-2,4,5-trimethylpyridin-3-ol analogue, regulates differentiation of Th1 and Th17 cells to ameliorate experimental autoimmune encephalomyelitis.

Youra KangMaheshwor TimilshinaTae-Gyu NamByeong-Seon JeongJae-Hoon Chang

Published in: Biological research (2017)

BJ-1108 treatment ameliorates inflammation and EAE by inhibiting Th1 and Th17 cells differentiation. Our findings suggest that BJ-1108 is a promising novel therapeutic agent for the treatment of inflammation and autoimmune disease.

Keyphrases

induced apoptosis
oxidative stress
cell cycle arrest
signaling pathway
multiple sclerosis
combination therapy
pi k akt
smoking cessation